Cagrilintide in Singapore: The Amylin Weight-Loss Drug Explained

Most of the weight-loss medicines making headlines belong to one family, the GLP-1 drugs. Cagrilintide is different. It works on a separate hormone pathway entirely, and it is the active partner in CagriSema, one of the most powerful weight-loss combinations yet tested. For people in Singapore following this space, that raises obvious questions: what is it, how well does it work, and can you get it here?

This guide answers those questions with current, accurate information. It explains what Cagrilintide is, how the amylin approach differs from the familiar injections, what the trial results actually showed, and the honest position on its availability in Singapore today.

What Is Cagrilintide?

Cagrilintide is a once-weekly injectable medication for weight management, developed by Novo Nordisk, the company behind Wegovy and Ozempic. It is a long-acting amylin analogue, which means it mimics a natural hormone called amylin.

Amylin is released by the pancreas alongside insulin after you eat. It helps control appetite and slows how quickly the stomach empties, telling the brain that you are full. Cagrilintide copies that signal in a longer-lasting form. What makes it notable is that it targets a completely different pathway from the GLP-1 drugs, which is why researchers are so interested in pairing the two.

How Is Cagrilintide Different From GLP-1 Drugs Like Wegovy and Mounjaro?

The difference is the hormone pathway each one uses. Wegovy and Mounjaro act on the GLP-1 system. Cagrilintide acts on the amylin system. Both reduce appetite and slow digestion, but they reach that result through separate biological routes.

This matters because two different pathways can be combined for a stronger effect than either alone. That is exactly the idea behind CagriSema, which pairs Cagrilintide with Semaglutide, the GLP-1 molecule found in Wegovy. By hitting two appetite systems at once, the combination aims to push weight loss further than a single-pathway drug can.

How Effective Is Cagrilintide for Weight Loss?

The results come from Novo Nordisk’s large Phase 3 REDEFINE trial programme. On its own, Cagrilintide produced an average weight loss of 11.8% of body weight at 68 weeks, with around one in three participants losing 15% or more. That is meaningful weight loss from a single-hormone approach.

The bigger numbers come from the combination. In the REDEFINE 1 trial, adults without diabetes taking CagriSema lost up to an average of 22.7% of their body weight over 68 weeks, one of the highest figures reported for an obesity medication. That combined result comfortably exceeds Semaglutide alone at around 16% and Cagrilintide alone at 11.8%, which shows the two pathways genuinely add to each other.

What Is CagriSema and How Does It Relate to Cagrilintide?

CagriSema is a fixed-dose combination of two medicines in a single weekly injection: Cagrilintide, the amylin analogue, and Semaglutide, the GLP-1 agonist. The name is a blend of the two ingredients. In simple terms, Cagrilintide is one half of CagriSema, and it is the half that brings the new amylin mechanism to the pairing.

Most of the public attention has gone to CagriSema because of its high weight-loss numbers, but the innovation people are tracking is Cagrilintide itself, since it opens up a second drug target for obesity beyond GLP-1.

What Are the Side Effects of Cagrilintide?

In the trials, Cagrilintide was generally well tolerated. The most common side effects were gastrointestinal, similar to the GLP-1 medicines, and included nausea, vomiting, diarrhoea, and constipation. These were mainly mild to moderate and tended to be strongest when starting treatment or moving to a higher dose, then easing over time.

As with any weight-management medication, it is not suitable for everyone, and it is designed to be used under medical supervision alongside a reduced-calorie diet and more physical activity. A proper medical assessment is what determines whether this class of drug is appropriate for a given person, which is one reason these treatments are prescription-only.

Is Cagrilintide Available in Singapore?

Not yet. This is the important part to be clear about. As of mid-2026, neither Cagrilintide on its own nor CagriSema has been approved by regulators anywhere, and both remain investigational medicines outside clinical trials.

Novo Nordisk filed its application with the US FDA in December 2025, with a review expected during 2026. It is not approved in the US or the EU, and it has not been registered with Singapore’s Health Sciences Authority. Until the HSA reviews and clears it, Cagrilintide cannot be legally prescribed or sold in Singapore. Any product marketed here now under names like Cagrilintide or CagriSema should be treated as a warning sign, since unapproved injectables bought online can be counterfeit, contaminated, or wrongly dosed.

The reassuring news is that effective, HSA-approved weight-loss options already exist here. Wegovy and Mounjaro are available through licensed providers, so medically supervised weight management does not depend on waiting for Cagrilintide.

What Should You Do if You Are Interested in Cagrilintide?

If the amylin approach interests you, the sensible step is not to chase an unapproved product, but to speak with a doctor about what is available and suitable for you today. A licensed physician can assess whether you are a candidate for medical weight management, start you on an approved treatment if appropriate, and keep you informed as new options like Cagrilintide move through regulatory review. Being already under proper medical care makes it straightforward to discuss or switch treatments when the landscape changes.

Speak with a Doctor Online

Sire is a men’s health telemedicine platform in Singapore. If you are considering medically supervised weight management, a licensed doctor can assess your suitability for an approved treatment and keep you updated as newer options like Cagrilintide become available. Start a weight management consultation or explore our other men’s health services.